At the news
? NEUTRALIMPACT 4/10 CLUSTER filed Mar 16, 2026 at 16:31 ET
United Therapeutics CEO Martine Rothblatt and other insiders engaged in a series of derivative exercises and open-market sales over the past week, with total open-market sales by insiders amounting to approximately $1.28 million. The majority of the activity consists of non-cash transactions (derivative exercises and tax withholdings), including a large tax-related share surrender worth $7.3 million by the CEO. The open-market selling was modest in dollar terms relative to the company's $23.1B market cap.
- CEO Martine Rothblatt sold 1,657 shares in open-market transactions totaling ~$1.07 million at prices between $522.88 and $534.99.
- EVP Paul Mahon sold 753 shares in open market for ~$397K.
- Director Malcolm Jan sold 45 shares for ~$24K; Director Judy Olian sold 200 shares for ~$107K.
- CEO and EVP exercised derivatives totaling 9,500 and 8,300 shares respectively on multiple dates, with exercise prices of $146.03 and $0.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access